• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed

    2/16/21 4:01:15 PM ET
    $HSKA
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care
    Get the next $HSKA alert in real time by email
    SC 13G/A 1 heskacorp_13gam1dec312020.htm SC 13G/A

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    SCHEDULE 13G

     

     

    Under the Securities Exchange Act of 1934

    (Amendment No. 1)*

      

     

    HESKA Corporation

    (Name of Issuer)

     

    COMMON STOCK, PAR VALUE $0.01 PER SHARE

    (Title of Class of Securities)

     

    42805E306

    (CUSIP Number)

     

    December 31, 2020

    (Date of Event Which Requires Filing of this Statement)

     

     

      

    Check the appropriate box to designate the rule pursuant to which this Schedule 13G is filed:

     

    [   ] Rule 13d-1(b)

    [X] Rule 13d-1(c)

    [   ] Rule 13d-1(d)

      

            

    * The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     
     

     

    CUSIP No.  42805E306
    (1) Names of Reporting Persons
      Park West Asset Management LLC  
    (2) Check the Appropriate Box if a Member of a Group (a) [    ]  
      (b) [    ]  
         
    (3) SEC Use Only
    (4) Citizenship or Place of Organization
      Delaware  
    Number of Shares Beneficially Owned By Each Reporting Person With
      (5) Sole Voting Power: 0*  
      (6) Shared Voting Power: 203,730*  
      (7) Sole Dispositive Power: 0*  
      (8) Shared Dispositive Power: 203,730*  
           
    (9) Aggregate Amount Beneficially Owned by Each Reporting Person
      203,730*  
    (10) Check if the Aggregate Amount  in Row (9) Excludes Certain Shares (See Instructions):
      [    ]  
    (11) Percent of Class Represented by Amount in Row (9)
      2.2%*  
    (12) Type of Reporting Person
      IA  
                   

     * See Item 4 for additional information. 

     

     

     
     

     

    CUSIP No.  42805E306
    (1) Names of Reporting Persons
      Park West Investors Master Fund, Limited  
    (2) Check the Appropriate Box if a Member of a Group (a) [    ]  
      (b) [    ]  
         
    (3) SEC Use Only
    (4) Citizenship or Place of Organization
      Cayman Islands  
    Number of Shares Beneficially Owned By Each Reporting Person With
      (5) Sole Voting Power: 0*  
      (6) Shared Voting Power: 185,350*  
      (7) Sole Dispositive Power: 0*  
      (8) Shared Dispositive Power: 185,350*  
           
    (9) Aggregate Amount Beneficially Owned by Each Reporting Person
      185,350*  
    (10) Check if the Aggregate Amount  in Row (9) Excludes Certain Shares (See Instructions):
      [    ]  
    (11) Percent of Class Represented by Amount in Row (9)
      2.0%*  
    (12) Type of Reporting Person
      CO  
                   

     * See Item 4 for additional information. 

     

     

     

     
     

     

    CUSIP No.  42805E306
    (1) Names of Reporting Persons
      Peter S. Park  
    (2) Check the Appropriate Box if a Member of a Group (a) [    ]  
      (b) [    ]  
         
    (3) SEC Use Only
    (4) Citizenship or Place of Organization
      United States of America  
    Number of Shares Beneficially Owned By Each Reporting Person With
      (5) Sole Voting Power: 0*  
      (6) Shared Voting Power: 203,730*  
      (7) Sole Dispositive Power: 0*  
      (8) Shared Dispositive Power: 203,730*  
           
    (9) Aggregate Amount Beneficially Owned by Each Reporting Person
      203,730*  
    (10) Check if the Aggregate Amount  in Row (9) Excludes Certain Shares (See Instructions):
      [    ]  
    (11) Percent of Class Represented by Amount in Row (9)
      2.2%*  
    (12) Type of Reporting Person
      IN  
                   

    * See Item 4 for additional information. 

     

     
     

     


    Item 1(a).  Name Of Issuer:  
      Heska Corporation, a Delaware Corporation (the “Company”)
    Item 1(b).  Address of Issuer’s Principal Executive Offices:
     

    3760 Rocky Mountain Avenue
    Loveland, Colorado 80538 

     

    Item 2(a).  Name of Person Filing:
     

    This report on Schedule 13G (this “Schedule 13G”) is being jointly filed by (i) Park West Asset Management LLC, a Delaware limited liability company (“PWAM”), (ii) Park West Investors Master Fund, Limited, a Cayman Islands exempted company (“PWIMF”) and (iii) Peter S. Park (“Mr. Park” and, collectively with PWAM and PWIMF, the “Reporting Persons”).

     

    Item 2(b).  Address of Principal Business Office or, if None, Residence:
     

    The address for the Reporting Persons is: 900 Larkspur Landing Circle, Suite 165, Larkspur, California 94939.

     

    Item 2(c).  Citizenship:
     

    PWAM is organized under the laws of the State of Delaware. PWIMF is a Cayman Islands exempted company. Mr. Park is a citizen of the United States.

     

    Item 2(d).  Title of Class of Securities:
                  Common Stock, par value $0.01 per share (the “Common Stock”).
    Item 2(e).  CUSIP No.:
                  42805E306

      

    Item 3.  If This Statement Is Filed Pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the Person Filing is a:
      Not Applicable.

      

     
     

      

    Item 4.  Ownership:  As reported in the cover pages to this report, the ownership information with respect to each of PWAM and Mr. Park is as follows:

     

     
      (a) Amount Beneficially Owned: 203,730*  
             
      (b) Percent of Class: 2.2%*  
             
      (c) Number of Shares as to which the person has:    

     

        (i) sole power to vote or to direct the vote: 0*   
               
        (ii) shared power to vote or to direct the vote 203,730*   
               
        (iii) sole power to dispose or to direct the disposition of: 0*   
               
        (iv) shared power to dispose or to direct the disposition of 203,730*   
               

       

    As reported in the cover pages to this report, the ownership information with respect to PWIMF is as follows:

     

     
      (a) Amount Beneficially Owned: 185,350*  
             
      (b) Percent of Class: 2.0%*  
             
      (c) Number of Shares as to which the person has:    

     

        (i) sole power to vote or to direct the vote: 0*   
               
        (ii) shared power to vote or to direct the vote 185,350*   
               
        (iii) sole power to dispose or to direct the disposition of: 0*   
               
        (iv) shared power to dispose or to direct the disposition of 185,350*   
               

    * PWAM is the investment manager to PWIMF and Park West Partners International, Limited, a Cayman Islands exempted company (“PWPI” and, collectively with PWIMF, the “PW Funds”). Mr. Park, through one or more affiliated entities, is the controlling manager of PWAM. As of December 31, 2020, PWAM and Mr. Park may be deemed to beneficially own 203,730 shares of Common Stock held in the aggregate by the PW Funds.

     

    The reported beneficial ownership percentage is based upon 9,454,771 shares of Common Stock issued and outstanding as of November 4, 2020, based on information reported by the Company in its Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 5, 2020.

     

     
     

     

    Item 5.  Ownership of Five Percent or Less of a Class:
      If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following:  [X]
    Item 6.  Ownership of More Than Five Percent on Behalf of Another Person:
      Not Applicable.
    Item 7.  Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person:
      Not Applicable.
    Item 8.  Identification and Classification of Members of the Group:
      Not Applicable.
    Item 9.  Notice of Dissolution of Group:
      Not Applicable.
    Item 10.  Certification:
     

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect. 

     

     
     

    SIGNATURE

              After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

      February 16, 2021  
         
      PARK WEST ASSET MANAGEMENT LLC  
         
         
      By: /s/ Grace Jimenez  
      Name: Grace Jimenez  
      Title: Chief Financial Officer  

     

      PARK WEST INVESTORS MASTER FUND, LIMITED  
         
      By:    Park West Asset Management LLC, its Investment Manager  
         
         
      By: /s/ Grace Jimenez  
      Name: Grace Jimenez  
      Title: Chief Financial Officer  

     

     

     

          /s/ Peter S. Park  
          Peter S. Park  
             
             

     

    Attention: Intentional misstatements or omissions of fact constitute

    Federal criminal violations (See 18 U.S.C. 1001)

     

     

     

     

     

     
     

     

    Exhibit Index

     

    Exhibit

    1.       Joint Filing Agreement, dated as of April 9, 2020, by and among Park West Asset Management, LLC, Park West Investors Master Fund, Limited and Peter S. Park (incorporated by reference to Exhibit 1 to the Schedule 13G filed with the Securities and Exchange Commission on April 9, 2020).

     

     

     

     

    Get the next $HSKA alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $HSKA

    DatePrice TargetRatingAnalyst
    1/6/2023$58.00Equal-Weight → Underweight
    Morgan Stanley
    3/1/2022$190.00 → $161.00Equal-Weight
    Morgan Stanley
    2/23/2022$300.00 → $250.00Overweight
    JP Morgan
    1/6/2022$210.00Overweight
    Piper Sandler
    11/18/2021$190.00Equal-Weight
    Morgan Stanley
    8/4/2021$240.00 → $305.00Overweight
    Piper Sandler
    7/12/2021$280.00Neutral → Buy
    Guggenheim
    More analyst ratings

    $HSKA
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Bee Vaccine Pioneer Dalan Secures $4.5M to Fuel Global Expansion and Product Development

      Key Points: $4.5 million in Series Seed 3 funding, led by Prime Movers Lab with participation from At One Ventures, bringing the company's total funding to $10 million. The funding will accelerate Dalan's product pipeline and facilitate its global expansion, aiming to protect the health of honeybees and secure the global food supply. Dalan Animal Health, Inc. ("Dalan"), a pioneering biotech company in insect health, today announced the successful closure of a $4.5 million Series Seed 3 funding round. The round was led by Prime Movers Lab with participation from At One Ventures, bringing Dalan's total funding to $10 million. The additional funding will enable Dalan to expedite its

      6/27/23 9:00:00 AM ET
      $HSKA
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • eXp World Holdings & Privia Health Group Set to Join S&P SmallCap 600

      NEW YORK, June 7, 2023 /PRNewswire/ -- S&P Dow Jones Indices will make the following changes to the S&P SmallCap 600 effective prior to the opening of trading on Wednesday, June 14: eXp World Holdings Inc. (NASD: EXPI) will replace Heska Corp. (NASD: HSKA). Mars Inc. is acquiring Heska in a deal expected to be completed soon pending final conditions.Privia Health Group Inc. (NASD: PRVA) will replace Ruth's Hospitality Group Inc. (NASD: RUTH). S&P 500 constituent Darden Restaurants Inc. (NYSE:DRI) is acquiring Ruth's Hospitality Group in a deal expected to be completed soon pending final conditions.Following is a summary of the changes that will take place prior to the open of trading on the

      6/7/23 6:37:00 PM ET
      $DRI
      $EXPI
      $HSKA
      $PRVA
      Restaurants
      Consumer Discretionary
      Real Estate
      Finance
    • Dalan Animal Health Ships First Honey Bee Vaccine to Tauzer Apiaries, Potentially Protecting 25 Million Bees.

      Dalan Animal Health, Inc. ("Dalan"), the biotech company pioneering insect health with the world's first honey bee vaccine, is proud to announce its first product shipment to a commercial beekeeper. The shipment is for Trevor Tauzer of Tauzer Apiaries in California and contains 500 doses, potentially protecting 25 million bees at an average of 50,000 bees per hive. This milestone follows the U.S. Department of Agriculture (USDA) granting a conditional license to Dalan's first-in-class honeybee vaccine earlier this year. The vaccine is indicated to protect honeybees against the devastating American Foulbrood disease caused by the bacteria Paenibacillus larvae. Honeybees are a critical co

      5/23/23 7:20:00 AM ET
      $HSKA
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care

    $HSKA
    Financials

    Live finance-specific insights

    See more
    • Heska Corporation Reports Fourth Quarter and Full Year 2022 Results

      Full Year Sales $257.3 Million, Full Year Gross Margin Up 150 Basis Points to 43.2% Full Year North America Lab Consumables Sales Up 8.7%, Total Active Subscriptions Up 18% LOVELAND, Colo., Feb. 28, 2023 /PRNewswire/ -- Heska Corporation (NASDAQ:HSKA, ", Heska", or ", Company", ))), a leading global provider of advanced veterinary diagnostic and specialty products, reported financial results in two segments (North America and International) for its fourth quarter and full year ended December 31, 2022. Fourth Quarter and Full Year 2022 and Year Over Year ("YOY") Metrics $ in mi

      2/28/23 8:00:00 AM ET
      $HSKA
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Heska Fourth Quarter and Full Year 2022 Financial Results and Earnings Call Scheduled for February 28, 2023

      LOVELAND, Colo., Feb. 8, 2023 /PRNewswire/ -- Heska Corporation (NASDAQ:HSKA, ", Heska", or the ", Company", ))), a leading global provider of advanced veterinary diagnostic and specialty solutions, will report its fourth quarter and full year 2022 financial performance in a press release before the market opens on Tuesday, February 28, 2023. The Company will also host an earnings call at 9 a.m. MT / 11 a.m. ET to discuss the results. To access the conference call: From within the United States, please dial 1-877-41-6152From outside of the United States, please dial 1-201-389-

      2/8/23 8:00:00 AM ET
      $HSKA
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Heska Corporation Completes Acquisition of LightDeck Diagnostics

      LOVELAND, Colo., Jan. 3, 2023 /PRNewswire/ -- Heska Corporation (NASDAQ: HSKA; "Heska" or the "Company"), a leading global provider of advanced veterinary diagnostic and specialty products and solutions, today announced the completion of acquisition of 100% of the shares of MBio Diagnostics, Inc. d/b/a LightDeck Diagnostics ("LightDeck"), a pioneer in planar waveguide fluorescence immunoassay diagnostics with strong manufacturing capabilities and research and development expertise (the "Acquisition").  The Acquisition, which was first announced on September 12, 2022, represent

      1/3/23 8:00:00 AM ET
      $HSKA
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care

    $HSKA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more

    $HSKA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more

    $HSKA
    Leadership Updates

    Live Leadership Updates

    See more

    $HSKA
    SEC Filings

    See more
    • Heska Corp downgraded by Morgan Stanley with a new price target

      Morgan Stanley downgraded Heska Corp from Equal-Weight to Underweight and set a new price target of $58.00

      1/6/23 8:09:57 AM ET
      $HSKA
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Morgan Stanley reiterated coverage on Heska with a new price target

      Morgan Stanley reiterated coverage of Heska with a rating of Equal-Weight and set a new price target of $161.00 from $190.00 previously

      3/1/22 9:56:21 AM ET
      $HSKA
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • JP Morgan reiterated coverage on Heska with a new price target

      JP Morgan reiterated coverage of Heska with a rating of Overweight and set a new price target of $250.00 from $300.00 previously

      2/23/22 8:14:03 AM ET
      $HSKA
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • SEC Form SC 13G/A filed by Heska Corporation (Amendment)

      SC 13G/A - HESKA CORP (0001038133) (Subject)

      4/10/23 2:50:12 PM ET
      $HSKA
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • SEC Form SC 13G/A filed by Heska Corporation (Amendment)

      SC 13G/A - HESKA CORP (0001038133) (Subject)

      2/14/23 4:07:17 PM ET
      $HSKA
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • SEC Form SC 13G/A filed by Heska Corporation (Amendment)

      SC 13G/A - HESKA CORP (0001038133) (Subject)

      2/10/23 10:12:43 AM ET
      $HSKA
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Heska Corporation Elects Dr. Joachim Hasenmaier to Board of Directors

      LOVELAND, Colo., Jan. 12, 2021 /PRNewswire/ -- Heska Corporation (NASDAQ: HSKA; "Heska" or "Company"), a leading global provider of advanced veterinary diagnostic and specialty products, appointed Dr. Joachim Hasenmaier, the former head of Boehringer Ingelheim Animal Health, to the Company's Board of Directors, effective January 11, 2021. Dr. Joachim Hasenmaier most recently served as a member of the board of managing directors of Boehringer Ingelheim, a world-leading, research-driven pharmaceutical company, where he oversaw the animal health and consumer healthcare businesses. Previously, as head of animal health of Boehringer Ingelheim, Dr. Hasenmaier led the rapid growth and expansion

      1/12/21 4:30:00 PM ET
      $HSKA
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • SEC Form 15-12G filed by Heska Corporation

      15-12G - HESKA CORP (0001038133) (Filer)

      6/23/23 6:01:38 AM ET
      $HSKA
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • SEC Form EFFECT filed by Heska Corporation

      EFFECT - HESKA CORP (0001038133) (Filer)

      6/14/23 12:15:09 AM ET
      $HSKA
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • SEC Form EFFECT filed by Heska Corporation

      EFFECT - HESKA CORP (0001038133) (Filer)

      6/14/23 12:15:13 AM ET
      $HSKA
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care

    $HSKA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Maples Sharon J.

      4 - HESKA CORP (0001038133) (Issuer)

      6/14/23 6:27:54 PM ET
      $HSKA
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • SEC Form 4 filed by Eyl Steven M.

      4 - HESKA CORP (0001038133) (Issuer)

      6/14/23 6:27:55 PM ET
      $HSKA
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • SEC Form 4 filed by Hasenmaier Joachim A.

      4 - HESKA CORP (0001038133) (Issuer)

      6/14/23 6:27:56 PM ET
      $HSKA
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care